IE000L4EH2K5
IE000L4EH2K5
Invesco S&P World Health Care ESG UCITS ETF Acc
Loading chart...
About this ETF
The Invesco S&P World Health Care ESG UCITS ETF Acc seeks to track the S&P Developed Ex-Korea LargeMidCap ESG Enhanced Health Care index. The S&P Developed Ex-Korea LargeMidCap ESG Enhanced Health Care index tracks large and mid cap companies from the health care sector. The stocks included are filtered according to ESG criteria (environmental, social and corporate governance).
TER
0.18%
Total Expense Ratio per year
Fund Size
€10.75M
Assets under management
Holdings
75
Underlying equities
Dividend Yield
0%
Accumulating
Fundamentals & Estimates
Weighted valuation multiples and analyst forecasts
Valuation Multiples
Weighted P/E
30.93
Weighted Fwd P/E
17.62
💰 Revenue Estimates
Current Year CY
+11.29% ⌀ 23 Analysts Coverage
Next Year NY
+7.33% ⌀ 23 Analysts Coverage
📈 EPS Estimates (Earnings Per Share)
Current Year CY
+5.49% ⌀ 24 Analysts Coverage
Next Year NY
+143.23% ⌀ 24 Analysts Coverage
Related ETFs
Amundi S&P World Information technology Screened UCITS ETF Acc
29.53 EUR
TER 0.18% 1Y +33.4%
Amundi S&P World Information technology Screened UCITS ETF Dist
29.15 EUR
TER 0.18% 1Y +33%
ETF Profile
Provider
Fund Type
ETF Type
Passive Inception Date
04/12/2023 (3 yrs)
Index Group
S&P Developed Region
World Country
-
Sector
Health Care Strategy
Social / Environmental Theme
-
Distribution Policy
Accumulating Replication
Full replication Sustainable
Yes 🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
5/7 Elevated
Diversification Score: 15/100 Low (Concentration Risk)
Diversification Score
15/100 Low (Concentration Risk)
3Y Volatility
14.9% p.a.
Max Drawdown (3Y)
-20.1%
Sharpe Ratio (3Y)
0.40
Beta Factor
1.03
Notes & Warnings
Fund Volume (AUM) ⚠️ Fund closure risk (< 50M € AUM)
⚠️ Elevated valuation: Avg P/E of 30.9
⚠️ Fund closure risk (< 50M € AUM)
🔴 Extreme top 10 holdings concentration: 64% of fund in top 10 positions.
🔴 Severe sector concentration risk: 100% in "Healthcare".
🔴 Extreme industry concentration: 66% in "Drug Manufacturers - General".
⚠️ Elevated Regulatory & Policy Risk: 100% in heavily regulated industries (defense, regulated utilities, healthcare policy).